Moahad S. Dar
Research Subjects
Moahad S. Dar has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna Ashline
Department of Primary Care, Greenville VA Healthcare Center, Greenville, NC, USA
1 shared publication - Anne Pernille Ofstad
Medical Department Boehringer Ingelheim Norway KS Asker Norway
1 shared publication Christoph Wanner
Würzburg University Clinic Würzburg Germany
1 shared publication- Hayden Barry Bosworth
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC 27701, USA
1 shared publication Junhong Zhang
Department of Primary Care, Greenville VA Healthcare Center, Greenville, NC, USA
1 shared publicationMichaela Mattheus
Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-13
The Diabetes Staging System (DSS): A Pilot Study Assessing Feasibility, Provider Engagement and Implementation Challenges of a Novel Staging System for Type 2 Diabetes
Introduction and Objective: Type 2 diabetes (DM2) currently lacks a standardized staging system that can be used to predict survival and guide providers towards guideline concordant care much like TNM staging does for cancer. We conducted a pilot study to assess the feasibility, provider engagement and implementation challenges of the DSS and examined if guideline concordant care improved especially SGLT2i/GLP-1a use in Veterans DM2 patients with cardiorenal disease. Methods: A 6-month pilot study implemented DSS in VA primary care clinics between December 2023–September 2024. Study visits were at baseline and 6 months. Primary outcome: the initiation of SGLT2i/GLP-1a in Veteran DM2 patients with CVD/CKD compared to baseline. Secondary outcomes: weight, blood pressure, hemoglobin A1C, glomerular filtration rate (GFR), and medication adherence compared to baseline. Inclusion criteria: Male or female Veterans between the ages of 18– 75 years with DM2 and ≥ 1 CV event and/or CKD and not on SGLT2i/GLP-1a. Exclusion criteria: Veterans with contraindications to SGLT2i/GLP-1 and/or a serious mental health disorder. Results: After baseline visit, all providers prescribed to 14/14 patients at least one of the medications with 12/14 prescribed SGLT2i and 2/14 prescribed GLP-1a. We found 13/14 (93%) patients to still be on at least one of the medications at 6 months. At 6 months compared to baseline, weight (216 lbs. ± 41 → 213 lbs. ± 39), blood pressure (141/76 ± 20/10 → 132/73 ± 17/10), A1C (7.7% ± 1.5% → 7.4% ± 0.8%) modestly decreased but GFR remained stable (64 mL/min ± 17 → 64 mL/min ± 19). Medication adherence was continued for all 13 patients (Medication possession ratio was ≥ 80%). Conclusion: DSS use was associated with increased SGLT2i/GLP-1a prescribing by VA primary care providers and medication adherence in Veterans DM2 patients with CVD/CKD. The DSS could help improve cardiorenal outcomes and guideline concordant in their DM2 patients in the future if larger studies can validate these findings. Clinical Trials Registration Number: NCT06142006.
- 1 April 2026
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 19, 1-13
Open AccessThe Diabetes Staging System (DSS): A Pilot Study Assessing Feasibility, Provider Engagement and Implementation Challenges of a Novel Staging System for Type 2 Diabetes
Introduction and Objective: Type 2 diabetes (DM2) currently lacks a standardized staging system that can be used to predict survival and guide providers towards guideline concordant care much like TNM staging does for cancer. We conducted a pilot study to assess the feasibility, provider engagement and implementation challenges of the DSS and examined if guideline concordant care improved especially SGLT2i/GLP-1a use in Veterans DM2 patients with cardiorenal disease. Methods: A 6-month pilot study implemented DSS in VA primary care clinics between December 2023–September 2024. Study visits were at baseline and 6 months. Primary outcome: the initiation of SGLT2i/GLP-1a in Veteran DM2 patients with CVD/CKD compared to baseline. Secondary outcomes: weight, blood pressure, hemoglobin A1C, glomerular filtration rate (GFR), and medication adherence compared to baseline. Inclusion criteria: Male or female Veterans between the ages of 18– 75 years with DM2 and ≥ 1 CV event and/or CKD and not on SGLT2i/GLP-1a. Exclusion criteria: Veterans with contraindications to SGLT2i/GLP-1 and/or a serious mental health disorder. Results: After baseline visit, all providers prescribed to 14/14 patients at least one of the medications with 12/14 prescribed SGLT2i and 2/14 prescribed GLP-1a. We found 13/14 (93%) patients to still be on at least one of the medications at 6 months. At 6 months compared to baseline, weight (216 lbs. ± 41 → 213 lbs. ± 39), blood pressure (141/76 ± 20/10 → 132/73 ± 17/10), A1C (7.7% ± 1.5% → 7.4% ± 0.8%) modestly decreased but GFR remained stable (64 mL/min ± 17 → 64 mL/min ± 19). Medication adherence was continued for all 13 patients (Medication possession ratio was ≥ 80%). Conclusion: DSS use was associated with increased SGLT2i/GLP-1a prescribing by VA primary care providers and medication adherence in Veterans DM2 patients with CVD/CKD. The DSS could help improve cardiorenal outcomes and guideline concordant in their DM2 patients in the future if larger studies can validate these findings. Clinical Trials Registration Number: NCT06142006.
- Open Access
- 6 March 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1372-1384
Cardiovascular outcomes trial data from EMPA‐REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetes
Aims: To apply the diabetes staging system (DSS), a novel disease staging system similar to what is used in oncology but designed to improve diabetes management, to three large type 2 diabetes (T2D) cardiovascular (CV) outcome trials to assess whether increasing DSS stage was associated with higher rates of all‐cause mortality (ACM) and/or CV death. Materials and Methods: The DSS uses discrete CV events (none to ≥3: Stage 1 to 4), end‐stage kidney disease (Stage 5) and microvascular complications (none to 3: A to D) to determine disease stage in individuals with T2D. The DSS stage for patients from the CAROLINA, EMPA‐REG OUTCOME and CARMELINA trials was determined. Incidence rates for ACM/CV death were calculated across DSS stages and Cox regression analyses were performed. Results: The risk of ACM or CV death increased with increasing DSS (Stage 1 to 5; P for trend P for trend P for trend = 0.0020 and 0.0005, respectively). In EMPA‐REG OUTCOME, having all three microvascular complications (Stage D), versus none, increased the risk of ACM and CV death ( P = 0.0015 and 0.0010, respectively). Conclusions: Applying the DSS across T2D clinical trial populations with different CV risk revealed a significantly increased risk of ACM and CV death with higher DSS stage. The DSS may merit assessment in other T2D populations and evaluation of the impact of additional outcomes, such as heart failure, could also be worthwhile.
- 6 March 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (5) , 1372-1384
Open AccessCardiovascular outcomes trial data from EMPA‐REG OUTCOME , CAROLINA and CARMELINA : Assessment of a novel staging system for type 2 diabetes
Aims: To apply the diabetes staging system (DSS), a novel disease staging system similar to what is used in oncology but designed to improve diabetes management, to three large type 2 diabetes (T2D) cardiovascular (CV) outcome trials to assess whether increasing DSS stage was associated with higher rates of all‐cause mortality (ACM) and/or CV death. Materials and Methods: The DSS uses discrete CV events (none to ≥3: Stage 1 to 4), end‐stage kidney disease (Stage 5) and microvascular complications (none to 3: A to D) to determine disease stage in individuals with T2D. The DSS stage for patients from the CAROLINA, EMPA‐REG OUTCOME and CARMELINA trials was determined. Incidence rates for ACM/CV death were calculated across DSS stages and Cox regression analyses were performed. Results: The risk of ACM or CV death increased with increasing DSS (Stage 1 to 5; P for trend P for trend P for trend = 0.0020 and 0.0005, respectively). In EMPA‐REG OUTCOME, having all three microvascular complications (Stage D), versus none, increased the risk of ACM and CV death ( P = 0.0015 and 0.0010, respectively). Conclusions: Applying the DSS across T2D clinical trial populations with different CV risk revealed a significantly increased risk of ACM and CV death with higher DSS stage. The DSS may merit assessment in other T2D populations and evaluation of the impact of additional outcomes, such as heart failure, could also be worthwhile.
- Open Access
- 1 November 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 845-853
TNM cancer staging: can it help develop a novel staging system for type 2 diabetes?
Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) estimates that more than 29 million people in the United States have diabetes, which often causes mortality from macrovascular complications and morbidity from microvascular complications. Despite these troubling facts, there is currently no widely accepted staging system for DM2 like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers can understand. Oncology is now entering the era of precision medicine where cancer treatment is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system and remains a largely invisible disease even though it kills more Americans and costs more to treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes Staging System for DM2 that utilizes macrovascular events, microvascular complications, estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.
- 1 November 2018
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 11, 845-853
Open AccessTNM cancer staging: can it help develop a novel staging system for type 2 diabetes?
Type 2 diabetes (DM2) constitutes 90%–95% of the diabetes cases and is increasing at an alarming rate in the world. The Centers for Disease Control and Prevention (CDC) estimates that more than 29 million people in the United States have diabetes, which often causes mortality from macrovascular complications and morbidity from microvascular complications. Despite these troubling facts, there is currently no widely accepted staging system for DM2 like there is for cancer. TNM oncologic staging has taken a complex condition like cancer and conveyed likelihood of survival in simple alpha-numeric terms that both patients and providers can understand. Oncology is now entering the era of precision medicine where cancer treatment is increasingly being tailored to each patient’s cancer. In contrast, DM2 lacks a staging system and remains a largely invisible disease even though it kills more Americans and costs more to treat than cancer. Is a comparable staging system for DM2 possible? We propose the Diabetes Staging System for DM2 that utilizes macrovascular events, microvascular complications, estimated glomerular filtration rate (GFR), and hemoglobin A1C to stage DM2.